# Measuring FA Progression

Keywords: Friedreich's ataxia, mFARS, SARA, neurological assessment, patient-reported outcomes, ADL, disease progression, clinical trials

> This page provides information about tools and scales used to measure the progression of Friedreich's ataxia (FA), including mFARS, SARA, and patient-reported outcome measures (PROMs), along with their clinical applications and significance.

## Details

- [The mFARS provides a detailed assessment of a Friedreich’s ataxia (FA) patient’s status](#scale): The modified Friedreich’s Ataxia Rating Scale (mFARS) is a validated tool used in clinical trials to assess FA progression and its impact on daily living activities.
- [Overview of the components of mFARS](#): mFARS evaluates four neurological domains, with scores reflecting the severity of FA progression and aiding in clinical management decisions.
- [The mFARS can predict the rate of FA progression and help inform management strategies](#): mFARS is used to predict disease progression, including loss of ambulation, enabling timely adjustments in management plans.
- [The Scale for the Assessment and Rating of Ataxia (SARA) is also frequently used to measure progression in FA](#): SARA is an ataxia-specific scale effective for monitoring advanced FA progression, though less sensitive in early stages compared to mFARS.
- [Overview of the 8 items of SARA](#): SARA evaluates eight neurological functions, with scores ranging from 0 (no ataxia) to 40 (severe ataxia), correlating with functional impairments.
- [FA-ADL is a validated subscale of FARS that reflects daily living with ataxia from the patient’s perspective](#): FA-ADL assesses functional impairments in nine daily activities, providing patient-reported insights into disease impact.
- [Other FA-specific PROMs](#): Additional patient-reported outcome measures (PROMs) evaluate psychosocial and cognitive aspects of FA, complementing clinical assessments.